Amicus Therapeutics Inc (FOLD)

09:00 AM

3,350,000 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Vestal Point Capital LP - MarketBeat

09:00 AM

08:02 AM

Sovereign s Capital Management LLC Makes New Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

08:02 AM

02:52 AM

Deutsche Bank AG Increases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

02:52 AM

May 20, 2025

Janus Henderson Group PLC Cuts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 20, 2025

May 20, 2025

Fabry Disease Market: Epidemiology, Therapies, Companies, - openPR.com

May 20, 2025

May 20, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World

May 20, 2025

May 19, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by D. E. Shaw & Co. Inc. - MarketBeat

May 19, 2025

May 19, 2025

Enzyme Replacement Therapy Market Generated Opportunities, - openPR.com

May 19, 2025

May 19, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Holdings Cut by BNP Paribas Financial Markets - MarketBeat

May 19, 2025

May 18, 2025

Orbimed Advisors LLC Increases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 18, 2025

May 17, 2025

Prosight Management LP Invests $8.67 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 17, 2025

May 16, 2025

Northern Trust Corp Has $31.76 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 16, 2025

May 16, 2025

Hudson Bay Capital Management LP Buys 379,800 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 16, 2025

May 16, 2025

Batten Disease Treatment Market Size, Outlook 2031 by Key - openPR.com

May 16, 2025

May 16, 2025

Parkman Healthcare Partners LLC Has $7.39 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 16, 2025

May 15, 2025

Balyasny Asset Management L.P. Lowers Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 15, 2025

May 14, 2025

Raymond James Financial Inc. Purchases Shares of 13,983 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

May 14, 2025

May 13, 2025

Is Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now? - Insider Monkey

May 13, 2025

May 12, 2025

Bayesian Capital Management LP Purchases 54,100 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 12, 2025

May 12, 2025

10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey

May 12, 2025

May 11, 2025

Schonfeld Strategic Advisors LLC Sells 97,156 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 11, 2025

May 09, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Algert Global LLC - MarketBeat

May 09, 2025

May 07, 2025

Marshall Wace LLP Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 07, 2025

May 07, 2025

Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference - GlobeNewswire

May 07, 2025

May 06, 2025

Oversold Conditions For Amicus Therapeutics (FOLD) - Nasdaq

May 06, 2025

May 06, 2025

Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200 - BioWorld MedTech

May 06, 2025

May 05, 2025

Pompe Disease Market Expected to Experience Major Growth - openPR.com

May 05, 2025

May 05, 2025

Voya Investment Management LLC Sells 743,492 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 05, 2025

May 04, 2025

Aquatic Capital Management LLC Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 04, 2025

May 04, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by PDT Partners LLC - MarketBeat

May 04, 2025

May 04, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Tower Research Capital LLC TRC - MarketBeat

May 04, 2025

May 04, 2025

Amicus Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo

May 04, 2025

May 04, 2025

Dark Forest Capital Management LP Purchases Shares of 38,148 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

May 04, 2025

May 02, 2025

UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, M - GuruFocus

May 02, 2025

May 02, 2025

UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, Maintains Buy Rating | FOLD Stock News - GuruFocus

May 02, 2025

May 02, 2025

Amicus Therapeutics (FOLD) Target Price Lowered by Goldman Sachs | FOLD Stock News - GuruFocus

May 02, 2025

May 02, 2025

FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls - TradingView

May 02, 2025

May 02, 2025

UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Dise - GuruFocus

May 02, 2025

May 02, 2025

UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Disease Outlook | FOLD Stock News - GuruFocus

May 02, 2025

May 02, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Call Transcript - Insider Monkey

May 02, 2025

May 02, 2025

UBS Adjusts Amicus Therapeutics Price Target to $22 From $21, Maintains Buy Rating - marketscreener.com

May 02, 2025

May 02, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 02, 2025

May 02, 2025

Dimerix and Amicus to commercialise DMX-200 in US - MSN

May 02, 2025

May 01, 2025

Amicus Therapeutics’ Earnings Call Highlights Growth and Strategic Moves - TipRanks

May 01, 2025

May 01, 2025

Amicus Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.07 - GuruFocus

May 01, 2025